New ways to improve treatments for dementia and cognitive decline
Novel Methods for Clinical Trials in Dementia and Cognitive Decline
This study is looking at how certain proteins from fat might affect how well the medication donepezil works for people with dementia, and it aims to find out which patients could benefit the most from this treatment, all while making it easy and safe for participants to join, especially those who aren't vaccinated against COVID-19.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-10837906 on NIH RePORTER |
What this research studies
This research investigates how certain proteins released by fat tissues, known as adipokines, may influence the effectiveness of the FDA-approved medication donepezil in treating dementia. The study will involve a clinical trial where participants may be assessed through telephone interviews to ensure safety and convenience, especially for those unvaccinated against COVID-19. By using innovative algorithms, the research aims to identify which patients are most likely to benefit from the treatment, potentially leading to more personalized care for individuals with dementia. The goal is to enhance the design and execution of future dementia-related clinical trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults experiencing cognitive decline or diagnosed with dementia, particularly those who may benefit from donepezil treatment.
Not a fit: Patients with non-dementia-related cognitive issues or those who are not eligible for donepezil treatment may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for dementia, enhancing cognitive function and quality of life for patients.
How similar studies have performed: Previous research has shown promise in using biomarkers and innovative assessment methods in dementia treatment, suggesting that this approach could yield valuable insights.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Royall, Donald R — University of Texas Hlth Science Center
- Study coordinator: Royall, Donald R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.